Plimack, E. R., Hammers, H. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., … Motzer, R. J. (2015). UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC). Asia-Pacific Journal of Clinical Oncology, 11, 129–129.

Plimack, Elizabeth R., Hans J. Hammers, Brian I. Rini, David F. McDermott, Bruce G. Redman, Timothy M. Kuzel, Michael R. Harrison, et al. “UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC).” Asia-Pacific Journal of Clinical Oncology 11 (2015): 129–129.

Plimack ER, Hammers HJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, et al. UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC). Asia-Pacific Journal of Clinical Oncology. 2015;11:129–129.

Plimack, Elizabeth R., et al. “UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC).” Asia-Pacific Journal of Clinical Oncology, vol. 11, 2015, pp. 129–129.

Plimack ER, Hammers HJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Xu L-A, Waxman IM, Motzer RJ. UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC). Asia-Pacific Journal of Clinical Oncology. 2015;11:129–129.